RIN-PF-305 (TETON2): A Randomized, Double-blind, Placebo-controlled, Multinational, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects with Progressive Pulmonary Fibrosis (TETON-PPF)
Grant
Overview
abstract
-
Treatment with inhaled treprostinil in the INCREASE study (RIN-PH-201) resulted in significant improvements in % predicted forced vital capacity (FVC) in subjects with pulmonary hypertension (PH) due to certain fibrotic lung diseases. Additionally, it reduced acute exacerbations of underlying lung disease in the overall population of PH associated with interstitial lung disease (PH-ILD). These improvements, combined with preclinical evidence of anti-fibrotic activity of treprostinil, suggest that inhaled treprostinil may offer a treatment option for subjects with fibrotic lung disease, including PPF.
date/time interval
awarded by